XML 48 R32.htm IDEA: XBRL DOCUMENT v3.25.2
Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q (Tables)
3 Months Ended 12 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Notes Tables    
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
  

June 30,

 
      

2024

 
  

2025

  

(as revised)

 
         

Equity based warrants to purchase common shares

  87,531   4,334 

Convertible Notes - common shares (1)

  -   33,250 

Convertible Notes - equity-based warrants to purchase common shares

  25,003   25,003 

Stock options granted under Company's incentive plan

  248,483   216,483 

Series A Warrants

  1,533,096   - 

Representative Warrants

  91,985   - 
         

Total potentially dilutive securities

  1,986,098   279,070 
  

March 31,

 
      

2024

 
  

2025

  

(as revised)

 
         

Equity based warrants to purchase common shares

  87,531   4,334 

Convertible Notes - common shares (1)

  -   33,250 

Convertible Notes - equity-based warrants to purchase common shares

  25,003   25,003 

Stock options granted under Company's incentive plan

  243,483   100,180 

Series A Warrants

  1,533,096   - 

Representative Warrants

  91,985   - 
         

Total potentially dilutive securities

  1,981,098   162,767 
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]
  

Three Months Ended June 30, 2024

 
  

Originally

Filed

  

Adjusted

for 1-for-20

Reverse

Stock Split

  

Correction

  

As Revised

 
                 

Net Loss (in thousands)

 $(2,699) $-  $-  $(2,699)

Loss per share - basic and diluted

 $(0.14) $(2.85) $0.65  $(2.20)

Weighted average shares outstanding - basic and diluted

  18,902,248   945,382   280,041   1,225,423 
  

Three Months Ended June 30, 2024

 
  

Originally

Filed

  

Adjusted

for 1-for-20

Reverse

Stock Split

  

Correction

  

As Revised

 
                 

Equity based warrants to purchase common shares

  5,344,569   267,231   (262,897)  4,334 

Convertible Notes - common shares

  665,000   33,250   -   33,250 

Convertible Notes - equity-based warrants to purchase common shares

  500,000   25,003   -   25,003 

Stock options granted under Company's incentive plan

  4,329,579   216,483   -   216,483 

Total potentially dilutive securities

  10,839,148   541,967   (262,897)  279,070 
  

Twelve Months Ended March 31, 2024

 
  

Originally

Filed

  

Adjusted

for 1-for-20

Reverse

Stock Split

  

Correction

  

As Revised

 
                 

Net Loss (in thousands)

 $(15,426) $-  $-  $(15,426)

Loss per share - basic and diluted

 $(1.05) $(21.09) $6.27  $(14.82)

Weighted average shares outstanding - basic and diluted

  14,626,282   731,372   309,348   1,040,720 
  

Twelve Months Ended March 31, 2024

 
  

Originally

Filed

  

Adjusted f

or 1-for-20

Reverse

Stock Split

  

Correction

  

As Revised

 
                 

Equity based warrants to purchase common shares

  5,744,569   287,231   (282,897)  4,334 

Convertible Notes - common shares

  665,000   33,250   -   33,250 

Convertible Notes - equity-based warrants to purchase common shares

  500,000   25,003   -   25,003 

Stock options granted under Company's incentive plan

  2,003,600   100,180   -   100,180 

Total potentially dilutive securities

  8,913,169   445,664   (282,897)  162,767